Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 839 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions: Sterotactic Body Radiotherapy/SBRT, Standard of care; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort); Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 80
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Advanced Solid Tumors
Interventions: U3-1287 (AMG888); Drug
Lead sponsor: U3 Pharma GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Refractory Germ Cell Tumors Expressing EGRF
Interventions: ZD1839 Iressa; Drug
Lead sponsor: Indiana University; Other
Eligibility: 15 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: EGF816; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Duarte, California • Orange, California • Santa Monica, California + 13 more

Conditions: Lung Cancer, EGFR Gene Mutation
Interventions: Circulating Tumor DNA (ctDNA) Assay; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 40 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 1 more

Conditions: Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
Interventions: IPI-504, Trastuzumab; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more

Conditions: Chronic Kidney Diseases, Acute Kidney Injury
Interventions: Creatinine, eGFR; Diagnostic Test
Lead sponsor: Nova Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Medley, Florida • Miami Gardens, Florida • Miami Lakes, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Oleclumab, Osimertinib, AZD4635; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Interventions: naquotinib, midazolam; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 7 more

Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions: erlotinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions: HBI-2376; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 11
States / cities: Duarte, California • Encinitas, California • Fullerton, California + 7 more

Conditions: Cervical Cancer, Cervix
Interventions: Tissue Repository; Genetic
Lead sponsor: University of New Mexico; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Advanced Solid Tumor
Interventions: BNT326, Pumitamig, Itraconazole, Paroxetine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more

Conditions: Carcinoma, Non-small-cell Lung
Interventions: Tarceva (erlotinib HCl, OSI-774 ); Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Alisertib, Endocrine therapy; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more

Conditions: Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
Interventions: Sym004, Futuximab, Modotuximab; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Irvine, California • Long Beach, California + 13 more

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, fluorouracil, paclitaxel; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions: A2B395, xT CDx with HLA-LOH assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Advanced Solid Tumors
Interventions: KBP-5209; Drug
Lead sponsor: Sihuan Pharmaceutical Holdings Group Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Indianapolis, Indiana • Houston, Texas • Salt Lake City, Utah

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Afatinib Dimaleate, Pembrolizumab; Drug · Biological
Lead sponsor: Jonathan Riess; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Nova Max Creatinine and eGFR Meter System

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib